Heron Therapeutics Inc. (HRTX) Raised to Hold at Zacks Investment Research
Heron Therapeutics Inc. (NASDAQ:HRTX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday.
According to Zacks, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. “
Several other research firms have also recently weighed in on HRTX. Brean Capital assumed coverage on shares of Heron Therapeutics in a report on Tuesday, October 4th. They issued a “buy” rating and a $41.00 price target on the stock. Lake Street Capital reissued a “buy” rating and issued a $45.00 price target on shares of Heron Therapeutics in a report on Tuesday, September 6th. JMP Securities reissued a “buy” rating on shares of Heron Therapeutics in a report on Friday, September 9th. Jefferies Group lowered their price target on shares of Heron Therapeutics from $46.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, October 3rd. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $38.00 price target on shares of Heron Therapeutics in a report on Tuesday, August 9th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Heron Therapeutics currently has a consensus rating of “Buy” and an average target price of $42.29.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/heron-therapeutics-inc-hrtx-raised-to-hold-at-zacks-investment-research.html
Shares of Heron Therapeutics (NASDAQ:HRTX) traded down 5.29% on Tuesday, hitting $16.29. The stock had a trading volume of 578,634 shares. Heron Therapeutics has a 12-month low of $15.13 and a 12-month high of $31.32. The company has a 50 day moving average of $18.38 and a 200-day moving average of $18.91.
Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by $0.21. On average, equities research analysts predict that Heron Therapeutics will post ($4.39) EPS for the current fiscal year.
In other news, insider Robert Rosen sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the transaction, the insider now directly owns 102,640 shares of the company’s stock, valued at $2,391,512. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 20.31% of the company’s stock.
Several hedge funds have recently bought and sold shares of HRTX. BlackRock Group LTD raised its stake in Heron Therapeutics by 9.0% in the second quarter. BlackRock Group LTD now owns 10,816 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 897 shares in the last quarter. Parametric Portfolio Associates LLC purchased a new stake in Heron Therapeutics during the second quarter valued at about $213,000. BlackRock Advisors LLC raised its stake in Heron Therapeutics by 13.3% in the second quarter. BlackRock Advisors LLC now owns 15,104 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 1,769 shares in the last quarter. State Board of Administration of Florida Retirement System raised its stake in Heron Therapeutics by 8.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 16,739 shares of the biotechnology company’s stock valued at $302,000 after buying an additional 1,283 shares in the last quarter. Finally, American International Group Inc. raised its stake in Heron Therapeutics by 8.1% in the second quarter. American International Group Inc. now owns 18,293 shares of the biotechnology company’s stock valued at $330,000 after buying an additional 1,369 shares in the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.